002901.SZ
大博医疗
SZSE · Healthcare · C 制造业 · CN
CNY 45.51
+2.94%Year over year
Reported trailing growth
- Revenue
- +19.2%
- EBITDA
- —
- EBIT
- +65.0%
- EPS
- +64.2%
- Free cash flow
- +249.9%
- Operating cash flow
- +110.7%
Forward estimates
Based on analyst estimates
- Revenue
- +10.8%
- EBITDA
- +38.6%
- EPS
- +23.4%
Three-year CAGR
- Revenue
- +21.9%
- EBITDA
- +52.1%
- EBIT
- +71.0%
- Net income
- +86.4%
- EPS
- +88.3%
- Free cash flow
- +306.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026